Literature DB >> 7915601

Mutations of the VHL tumour suppressor gene in renal carcinoma.

J R Gnarra1, K Tory, Y Weng, L Schmidt, M H Wei, H Li, F Latif, S Liu, F Chen, F M Duh.   

Abstract

Multiple, bilateral renal carcinomas are a frequent occurrence in von Hippel-Lindau (VHL) disease. To elucidate the aetiological role of the VHL gene in human kidney tumorigenesis, localized and advanced tumours from 110 patients with sporadic renal carcinoma were analysed for VHL mutations and loss of heterozygosity (LOH). VHL mutations were identified in 57% of clear cell renal carcinomas analysed and LOH was observed in 98% of those samples. Moreover, VHL was mutated and lost in a renal tumour from a patient with familial renal carcinoma carrying the constitutional translocation, t(3;8)(p14;q24). The identification of VHL mutations in a majority of localized and advanced sporadic renal carcinomas and in a second form of hereditary renal carcinoma indicates that the VHL gene plays a critical part in the origin of this malignancy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7915601     DOI: 10.1038/ng0594-85

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  461 in total

1.  The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity.

Authors:  D Mukhopadhyay; B Knebelmann; H T Cohen; S Ananth; V P Sukhatme
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

Review 2.  HIF hydroxylation and the mammalian oxygen-sensing pathway.

Authors:  Michal Safran; William G Kaelin
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

3.  New antiangiogenic agents for renal cell carcinoma: interferon alfa and thalidomide.

Authors:  Ronald M Bukowski
Journal:  Curr Oncol Rep       Date:  2004-03       Impact factor: 5.075

Review 4.  Circulating biomarkers in advanced renal cell carcinoma: clinical applications.

Authors:  Maria Hernandez-Yanez; John V Heymach; Amado J Zurita
Journal:  Curr Oncol Rep       Date:  2012-06       Impact factor: 5.075

5.  Carminomycin I is an apoptosis inducer that targets the Golgi complex in clear cell renal carcinoma cells.

Authors:  Girma M Woldemichael; Thomas J Turbyville; W Marston Linehan; James B McMahon
Journal:  Cancer Res       Date:  2011-01-01       Impact factor: 12.701

6.  Reduced expression of Slit2 in renal cell carcinoma.

Authors:  Wei-Jie Ma; Yu Zhou; Dan Lu; Dong Dong; Xiao-Jun Tian; Jie-Xi Wen; Jun Zhang
Journal:  Med Oncol       Date:  2013-11-15       Impact factor: 3.064

7.  Inverse association between programmed death ligand 1 and genes in the VEGF pathway in primary clear cell renal cell carcinoma.

Authors:  Richard W Joseph; Mansi Parasramka; Jeanette E Eckel-Passow; Dan Serie; Kevin Wu; Liuyan Jiang; Krishna Kalari; R Houston Thompson; Thai Huu Ho; Erik P Castle; John Cheville; Eugene D Kwon; E Aubrey Thompson; Alexander Parker
Journal:  Cancer Immunol Res       Date:  2013-08-29       Impact factor: 11.151

8.  Influence of the RNA-binding protein HuR in pVHL-regulated p53 expression in renal carcinoma cells.

Authors:  Stefanie Galbán; Jennifer L Martindale; Krystyna Mazan-Mamczarz; Isabel López de Silanes; Jinshui Fan; Wengong Wang; Jochen Decker; Myriam Gorospe
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

9.  Carbonic anhydrase IX has chaperone-like functions and is an immunoadjuvant.

Authors:  Yanping Wang; Xiang-Yang Wang; John R Subjeck; Hyung L Kim
Journal:  Mol Cancer Ther       Date:  2008-12       Impact factor: 6.261

10.  Congenital anomalies and genetic disorders in families of children with central nervous system tumours.

Authors:  S M Jones; P C Phillips; P T Molloy; B J Lange; M N Needle; J A Biegel
Journal:  J Med Genet       Date:  1995-08       Impact factor: 6.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.